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SUMMARY
Estrogenic and carcinogenic activity are shown to be separable properties. 2-Fluoroestra-
diol, a modified estrogen, did not induce renal clear-cell carcinoma in male Syrian
hamsters despite its estrogenic potency, which is comparable to that of estradiol. 4-
Fluoroestradiol, also a potent estrogen, did induce renal clear-cell carcinoma in this
animal model, but more slowly than estradiol. 2,4-Dideuterioestradiol was found to be as
estrogenic and also as carcinogenic as estradiol itself.
Prolonged treatment of experimental animals with ex-
ogenous estrogens has been reported (1, 2) to induce
tumors of the testes, cervix and uterus, lymphoid tissues,
mammary tissue, adrenal cortex, kidney, and anterior
pituitary gland. The exact mechanism of tumor induction
by these hormones is unknown. It has been proposed (3,
4), however, that the ring-A hydroxylated estrogens, the
primary products of estradiol metabolism (5), although
almost devoid of estrogenic activity, could be responsible
for the carcinogenic action of estradiol. These metabo-
lites, 2- and 4-hydroxyestradiol and 2- and 4-hydroxyes-
trone, are the major biotransformatory products of estra-
diol in most species (5) and are known to bind covalently
to protein or peptides (6-8) and to DNA (9) in vitro.
Such binding to protein can be suppressed by prior
methylation of the catechol using S-adenosylmethionine-
o-catechol-O-methyltransferase, i.e., conversion to a less
reactive methoxyestradiol or methoxyestrone (10).
If metabolic activation to a catechol is indeed a nec-
essary step in the chain of events resulting in tumors,
then interference with metabolic oxidations should in-
hibit carcinogenesis. This concept was tried successfully
by Li and Li (11), who were able to inhibit diethylstilbes-
trol-induced renal carcinoma in Syrian hamsters by
chronic administration of inhibitors of microsomal cyto-
chrome P-450 enzymes. Another approach to prevention
of carcinogenesis would be the use of estrogens modified
to prevent oxidation to carcinogenic catechol estrogens.
Biotransformation reactions can indeed be influenced by
appropriate chemical substituents (12). The metabolic
pathways ofcaffeine, antipyrene, methsuximide (13), and
cyclophosphamide (14) were altered by replacing hydro-
gen with deuterium at defined sites of the drug molecule.
Furthermore, replacement of hydrogen with fluorine in
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positions prone to oxidation has been successfully used
(15) to make modified ecdysone insect hormones which
were not metabolically deactivated when administered
to insects.
Deuterium or fluorine as the metabolism-inhibiting
substituent is an appropriate choice for modifying estro-
gens, since either element can be substituted for hydro-
gen with little or no change in the conformation of the
molecule. This ensures recognition of the modified estro-
gens by hormone receptors and, therefore, their retained
estrogenic activity.
To test the possible prevention of estrogen-induced
carcinogenesis, 2-fluoroestradiol, 4-fluoroestradiol, and
2,4-dideuterioestradiol were synthesized according to
published procedures (16, 17) and their biological activi-
ties were tested. 2,4-Dideuterioestradiol (after trimeth-
ylsilylation) was analyzed by gas chromatography/mass
spectrometry and found to be chromatographically pure.
The mass spectrum was identical with that of the tri-
methylsilyl derivative of estradiol except that masses
were shifted by 2 a.m.u. The following isotopic purity
was observed: 92% of 2,4-dideuterioestradiol, 6% of mon-
odeutenoestradiol, and 2% of estradiol. The purity of the
two fluorinated estradiols and their structural identities
were checked by mass spectrometry. The spectrum of 4-
fluoroestradiol was found to be identical with that of an
authentic sample obtained from the Drug Synthesis and
Chemistry Branch, National Institutes of Health (Be-
thesda, Md.). The spectrum of 2-fluoroestradiol was that
of a pure compound and was characteristic of the struc-
tural features of this material. Each of the fluorinated
estradiols was prepared in a seven-step synthesis. The
purity and the structural identity of each of the precursor
compounds were also checked by mass spectrometric
analysis. At the end of the biological experiments, when
the hamsters were killed, the remains of the estrogen
implants were excised, and the contents were extracted
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into methanol and analyzed by gas chromatography/
mass spectrometry (after trimethylsilylation). The anal-
ysis confirmed the composition of the pellet material: the
corresponding fluoroestradiol and cholesterol.
The estrogenicity of the modified estrogens was meas-
ured by using two different methods. The most common
method, increase in uterine wet weight in ovariectomized,
immature rats upon administration of estrogen, showed
that the fluorinated estrogens are approximately as es-
trogenic as estradiol (Table 1). Furthermore, the weights
of both testes of the male Syrian hamsters, which were
used in the in vivo carcinogenicity assay, were measured
on the 224th day after s.c. implantation of 25-mg pellets
of estrogen. The weights were measured in grams and
expressed as percentage of total body weight. Treatment
of animals with modified estrogens or with estradiol
resulted in the shrinking of the testes to approximately
10% of the weights of testes in untreated hamsters. The
estrogenicity measurements carried out in our laboratory
compare well with experiments reported by Heiman et
at. (18) and Katzenellenbogen et al. (19). These authors
reported the estrogen receptor binding affinity of the
fluorinated estrogens. When expressed as ratios of asso-
ciation constants (Ka compound/Ka estradiol) X 100, the bind-
ing affinity of 2-fluoroestradiol was found to be 86; that
of 4-fluoroestradiol was 128. In this procedure, the bind-
ing affinity of estradiol was defined as 100. These data
confirmed the reported findings that 4-fluoroestradiol
was slightly more estrogenic, and 2-fluoroestradiol
slightly less estrogemc, than estradiol. In more recent
experiments, Pfeiffer et al. (20) measured the estrogen
receptor affinity of 2- and 4-fluoroestradiol in cytosol of
the hypothalamus-preoptic area, the pituitary, and the
uterus. The fluorinated estradiols were found to have
high receptor affinity. Furthermore, the biological re-
TABLE 1





% total body wt mg
2-Fluoroestradiol 0.18-0.25 92 ± 20
4-Fluoroestradiol 0. 18-0.28 118 ± 19
2,4-Dideuterioestradiol 0. 19-0.24 nd
Estradiol 0. 12-0.26 114 ± 20
Control 1.85-2.06 33 ± 6
a Data shown were recorded from the same animals used in the
carcinogenicity testing (Table 2). The estrogen treatment of these
animals is described in Footnote a, Table 2. Two hundred and twenty-
four days after treatment with estrogens began, hamsters were weighed
and killed; both testes were excised and their weights were measured in
grams. Data presented are the ranges of testis weights from four
animals in each group.
F, Female Sprague-Dawley rats, 3-4 weeks of age, were ovariecto-
mized. Four days after ovariectomy the animals were separated into
four groups of equal group weight (17 animals/group, average weight
90 ± 1 g/animal), and estrogen treatment was begun. Each animal
received an s.c. injection of estrogen (3.5 jg of estrogen in 0.7 ml of
saline per animal) once daily for 3 days. Saline solutions were prepared
by dissolving the estrogen in ethanol and diluting this solution with
saline until a mixture of 5% ethanol/95% saline was obtained. The
control group received only saline. On the 4th day, the animaLs were
killed, and the uteri were excised, freed of luminal fluid, and weighed.
Data are averages of uterine wet weights ± standard deviations.
sponses to the fluorinated estrogens (such as elicitation
of luteinizing hormone surges, of proceptivity, and of
lordosis behavior) in rats were comparable with those
elicited by estradiol (21, 22).
The carcinogenicity of the modified estrogens was
measured in male Syrian hamsters in vivo. This tumor
model was well described by Kirkman (23), and was later
investigated by McGregor et at. (24), by Sirbasku and
Kirkland (25), and by this laboratory.’ Estrogen, and
estrogen alone, causes renal clear-cell carcinoma in 100%
of the male animal population when exposed to s.c.
implants of this hormone (23). This kidney tumor is
estrogen-induced and estrogen-dependent for develop-
ment and growth (23-25). Failure to resupply estrogen
every 3 months or surgical removal of the implants
resulted (23, 24) in tumor regression within a few weeks.
Similarly, a tumor cell line derived from the Syrian
hamster renal clear-cell carcinoma was found (4, 25) to
be strongly estrogen-dependent in vivo, showing 90%
tumor regression 10 days after removal of the source of
estrogen. The incidence of spontaneous kidney tumor in
Syrian hamsters without estrogen treatment is very low
(23).
Male hamsters (15-20 animals/group) received im-
plants of estrogen (Table 2) and were resupplied with
pellets of the same composition approximately 3 months
later. Two hundred and twenty-four days after the begin-
fling of the experiment, four animals per group were
killed and their kidneys were examined histologically for
the occurrence of renal clear-cell carcinoma. Whereas all
of the animals treated with estradiol or with 2,4-dideu-
terioestradiol had developed visible renal tumors, none
of the animals treated with 2-fluoroestradiol showed
evidence of kidney tumor induction (Table 2). Histolog-
icafly, kidneys from this group were indistinguishable
from kidneys of totally untreated animals. Among the
four animals treated with 4-fluoroestradiol, one had small
tumors and the kidneys of two animals were judged to be
preneoplastic.
Similar results were obtained when, 279 days after the
initial pelleting with estrogens, a second group of male
hamsters was examined for renal clear cell carcinoma.
Again, all animals treated with estradiol (the positive
control in this experiment) had renal tumors. All animals
treated with 2,4-dideuterioestradiol showed large, multi-
pie tumor nodules on their kidneys. Therefore, all ani-
mals treated with this deuterated estrogen were killed at
this time, since the carcinogenic activity of this corn-
pound was not different from that of estradiol itself.
None of the five animals treated with 2-fluoroestradiol
showed any kidney neoplasms. Three of six animals with
4-fluoroestradiol implants showed renal clear-cell carci-
noma. Again, these results were confirmed by histological
examination.
The remaining animals were killed 345 days after the
initial s.c. implantation of estrogen pellets and their
kidneys were excised and examined for the occurrence of
renal clear-cell carcinoma. By visual inspection, none of
the animals had visible tumors; i.e., not even animals
treated with estradiol showed renal neoplasms. The his-
tological examination of these kidneys revealed small,
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TABLE 2
In vito carcinogenicity of modified estrogens
Treatment”
(no. of animals)
No. of animals lost or
deadh
No. of animals with tumors’ (no. of animals examined) on various
days after s.c. implantation of estrogen
224 days 279 days 345 days
Estradiol (18) 5 4 (4) 5 (5) 0 (4)
2,4-Dideuterioestradiol (20) 3 4 (4) 13 (13) -
2-Fluoroestradiol (15) 3 0 (4) 0 (5) 0 (3)
4-Fluoroestradiol (15) 2 1 (4) 3 (6) 3 (3)
Control (10) 0 0 (3) 0 (3) 0 (4)
(1 Male Syrian hamsters, 3-4 weeks of age (Harlan/Sprague-Dawley, Madison, Wisc.), were given a 25-mg s.c. implant consisting of 10%
cholesterol and 90% estrogen. A second 25-mg pellet of the same composition was implanted 106 days after the initial estrogen treatment. A lack
of fluorinated estrogens prevented repelleting of the animals approximately 6 months after the initial estrogen treatment. Estrogen treatment was
carried out according to the procedure of Kirkman (23). Control animals were left untreated.
F, Number of animals lost or dead from various causes during the course of the experiment. Tumors appear approximately 6 months after
pelleting with estrogen (23, 25). Therefore, this group included all hamsters found dead during the first 6 months of the experiment, since tumors
were not expected and not evident in the kidneys of these animals. Hamsters found dead after 6 months were also included in this group, if their
kidneys could not be recovered. Two dead hamsters with recoverable kidneys were included in the nearest examination group at 279 days (one
animal treated with 2,4-dideuterioestradiol with tumorous kidneys and one animal treated with 4-fluoroestradiol without renal carcinoma).
( The hamsters were divided into three groups. The first group was examined 224 days, the second 279 days, and the third 345 days after the
initial implantation of estrogen. The animals were decapitated, and the kidneys were excised and inspected visually for the occurrence of renal
clear-cell carcinoma. Sections were prepared of all kidneys and studied histologically. The results of the histological examinations are tabulated.
regressed tumors in kidneys of animals treated with 4-
fluoroestradiol. This last group of hamsters did not re-
ceive reimplants and so had been without estrogen treat-
ment for approximately 7% months; therefore any exist-
ing tumors probably had regressed, and went undetected
in the histological studies. Kidney carcinomas in 4-fluo-
roestradiol-treated hamsters did not regress completely,
probably because of the longer-lasting estrogenic activity
of this modified estrogen. Since in this third group none
of the estradiol-treated hamsters (the positive control in
this experiment) showed evidence of carcinomas, the
significance of the results obtained 345 days after the
beginning of the experiment remains very questionable.
In the evaluation of the carcinogenic activity of fluori-
nated estrogens, the data obtained at this third time
point are not useful owing to the lack of a positive control
and the long time period (7#{189}months) between the last
implantation of estrogens and the day of sacrifice.
The clear and unquestionable results from the first two
kidney examinations described above establish 2-fluo-
roestradiol as highly estrogenic yet noncarcinogenic in
the animal model used. 4-Fluoroestradiol was carcino-
genic with a longer induction period for renal tumors
than was established for estradiol. The separation of
estrogenic from carcinogenic action, reported for the
modified estrogen above, shows that these properties are
not intrinsically associated with each other but depend
on the chemical and structural characteristics of the
hormone molecule. The noncarcinogenic estrogens may
be used as a tool with which to study the promotion of
estrogen-dependent tumors separately from the tumor-
inducing properties of estrogens.
The mechanism of action of the noncarcinogenic estro-
gens is yet unknown. Since the C-F bond is among the
strongest bonds known to organic chemists (26), it is
suspected that prevention of tumorigenesis is due to the
inability of oxidizing enzymes to cleave the C-F bond
on fluoroestradiols and the resulting inability to form
catechols. Pfeiffer et at. (20) and Krey et at. (22) tested
the fluorinated estradiols for catechol formation by using
rat liver microsomes and a methylation system (catechol-
O-methyltransferase, [3H]sadenosylmethionine) to con-
vent newly synthesized catechol estrogens to stable [3H]
methyl ethers. Considering that the enzyme preparation
contained primarily 2-hydroxylases, the extremely low
rate of catechol estrogen formation seen with 2-fluoroes-
tradiol was taken as evidence for only 4-hydroxylation.
The rate of catechol formation from 4-fluoroestradiol,
which was stifi less than that seen for estradiol itself, was
assumed to reflect only 2-hydroxylation.
The carcinogenic activity of the estrogens tested
closely reflects their ability to be converted to catechol
estrogens. The extremely low rate of conversion of 2-
fluoroestradiol to catechol estrogen (20, 22) probably
corresponds to the diminished carcinogenic activity of
this modified estrogen. 4-Fluoroestradiol, which was car-
cinogenic but with a longer induction period than found
for estradiol, was converted to catechols with a rate
between that found for 2-fluoroestradiol and estradiol.
In analogous experiments, fluorination of polycycic
aromatic hydrocarbons at specific sites of the ring system
was shown (27, 28) to result in a reduction of tumori-
genicity and of dihydrodiol formation.
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